Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $16.90.

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Monday, April 22nd. Piper Sandler started coverage on Roivant Sciences in a research report on Friday, January 5th. They issued an “overweight” rating and a $20.00 price target for the company. The Goldman Sachs Group boosted their price objective on shares of Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Bank of America increased their target price on shares of Roivant Sciences from $11.00 to $12.00 and gave the company a “neutral” rating in a research note on Tuesday, January 2nd. Finally, TheStreet raised shares of Roivant Sciences from a “d” rating to a “c+” rating in a research note on Tuesday, February 13th.

Insider Activity

In related news, COO Eric Venker sold 96,950 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.92, for a total value of $1,058,694.00. Following the transaction, the chief operating officer now owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Citigroup Inc. grew its position in shares of Roivant Sciences by 45.6% during the 3rd quarter. Citigroup Inc. now owns 326,431 shares of the company’s stock worth $3,813,000 after buying an additional 102,279 shares in the last quarter. Morgan Stanley lifted its stake in Roivant Sciences by 48.7% in the third quarter. Morgan Stanley now owns 19,311,631 shares of the company’s stock worth $225,560,000 after acquiring an additional 6,324,915 shares during the period. Deerfield Management Company L.P. Series C grew its holdings in Roivant Sciences by 18.4% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 1,604,487 shares of the company’s stock worth $18,740,000 after acquiring an additional 249,513 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Roivant Sciences during the 3rd quarter valued at about $4,200,000. Finally, Corton Capital Inc. raised its holdings in shares of Roivant Sciences by 87.2% in the 3rd quarter. Corton Capital Inc. now owns 27,236 shares of the company’s stock valued at $318,000 after purchasing an additional 12,685 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

ROIV stock opened at $11.03 on Friday. Roivant Sciences has a 52 week low of $8.06 and a 52 week high of $13.24. The firm has a market capitalization of $8.89 billion, a P/E ratio of 2.12 and a beta of 1.34. The company has a fifty day simple moving average of $10.92 and a two-hundred day simple moving average of $10.37. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. The firm had revenue of $37.14 million during the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. Analysts anticipate that Roivant Sciences will post -1.36 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.